SER-109, an Investigational Microbiome Drug to Reduce Recurrence after Clostridioides difficile Infection: Lessons Learned from a Phase 2 Trial

Barbara H. McGovern, Christopher B. Ford, Matthew R. Henn, Darrell S. Pardi, Sahil Khanna, Elizabeth L. Hohmann, Edward J. O'Brien, Christopher A. Desjardins, Patricia Bernardo, Jennifer R. Wortman, Mary Jane Lombardo, Kevin D. Litcofsky, Jonathan A. Winkler, Christopher W.J. McChalicher, Sunny S. Li, Amelia D. Tomlinson, Madhumitha Nandakumar, David N. Cook, Roger J. Pomerantz, John G. AuninšMichele Trucksis

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'SER-109, an Investigational Microbiome Drug to Reduce Recurrence after Clostridioides difficile Infection: Lessons Learned from a Phase 2 Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences